Continuous subcutaneous insulin infusion in patients with diabetes mellitus

Therapeutic Apheresis

Volumn 7, Issue 2, 2003, Pages 232-237

  Schiel, Ralf ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Artificial pancreas; Continuous subcutaneous insulin infusion; Diabetes mellitus type 1, type 2; Glycated hemoglobin; Insulin pump

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ARTICLE; ARTIFICIAL PANCREAS; CLINICAL TRIAL; DIABETES CONTROL; DRUG INFUSION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; KETOACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; HUMANS; HYPOGLYCEMIA; INSULIN INFUSION SYSTEMS; QUALITY OF LIFE;

EID: 0037631797     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00038.x     Document Type: Article

References (43)

1. Tuomilehto J. Diabetes - A problem for millions of people and their families in the European Union. Diabetologia 1997;8:12-14.
2. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.
3. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
4. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 1995;28:103-17.
5. UK prospective diabetes study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
6. Slama G, Hautecouverture M, Assan R, Tchobroutsky G. One to five days of continuous intravenous insulin infusion in seven diabetic patients. Diabetes 1974;23:732-8.
7. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: An approach to achieving normoglycaemia. Br Med J 1978;1:204-7.
8. American Diabetes Association. Policy statement: Continuous subcutaneous insulin infusion. Diabetes 1985;34:946-7.
9. Disetronic Medical Systems AG. Disetronic diabetes care. International pump survey, 1998. Burgdorf, Switzerland: Distronic Medical Systems AG, 1998.
10. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Metaanalysis of randomised controlled trials. Br Med J 2002;324:705-17.
11. Bott U, Jörgens V, Grüsser M, Bender R, Mühlhauser I, Berger M. Predictors of glycaemic control in type 1 diabetic patients after participation in an intensified treatment and teaching program. Diab Med 1994;11:362-71.
12. Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: Its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diab Care 1982;5:479-84.
13. Terént A, Hagfall O, Cederholm U. The effect of education and self-monitoring of blood glucose on glycosylated hemoglobin in type 1 diabetes. A controlled 18-month trial in a representative population. Acta Med Scand 1985;217:47-53.
14. Kademann A, Schiel R, Hunger-Dathe W, Müller UA. Effektivität der Insulinpumpentherapie im Vergleich zur intensivierten konventionellen Insulintherapie. Diab Stoffiv 1999;8:118-24 (in German).
15. Berger M, Mühlhauser I. Implementation of intensified insulin therapy: a European perspective. Diab Med 1995;12:201-8.
16. Jörgens V, Grüßer M, Bott U, Mühlhauser I, Berger M. Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia 1993;36:99-105.
17. Mühlhauser I, Jörgens V, Berger M et al. Bicentric evaluation of a teaching and treatment program for type 1 (insulin-dependent) diabetic patients: Improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia 1983;25:470-6.
18. Schiel R, Müller UA, Ulbrich S. Long-term efficacy of a 5-day structured teaching program for intensified conventional insulin therapy and risk for severe hypoglycemia. Diab Res Clin Pract 1997;35:41-8.
19. Diabetes Control and Complication Trial Research Group. Implementation of treatment protocols in the diabetes control and complications trial. Diab Care 1995;18:361-76.
20. Brink SJ, Stewart C. Insulin pump treatment in insulin-dependent diabetes mellitus: Children, adolescents and young adults. JAMA 1986;255:617-21.
21. Chantelau E, Spraul M, Mühlhauser I, Gause R, Berger M. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989;32:421-6.
22. Mecklenburg RS, Benson EA, Benson JW et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 1984;252:3265-9.
23. Nathan DM, Lou P, Avruch J. Intensive conventional and insulin pump therapies in adult type 1 diabetes. Ann Int Med 1982;97:31-6.
24. Rönn B, Mathiesen ER, Vang L, Lörup B, Deckert T. Evaluation of insulin pump treatment under routine conditions. Diab Res Clin Pract 1987;3:191-6.
25. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diab Care 1996;19:324-7.
26. Schiel R, Müller UA, Sprott H et al. The JEVIN trial: a population-based survey on the quality of diabetes care in Germany: 1994/1995 compared with 1989/1990. Diabetologia 1997;40:1350-7.
27. Müller UA, Ross IS, Klinger H, Geisenheiner S, Chantelau ER. Quality of centralized diabetes care: a population-based study in the German Democratic Republic 1989-90. Acta Diabetol 1993;30:166-72.
28. Müller UA, Hunger-Dathe W, Kobes M, Reuber E, Kirchner D. Qualität der Stoffwechseleinstellung bei Typ-I-Diabetikern ein Jahr nach Teilnahme an einem strukturierten Behandlungsprogramm für intensivierte Insulintherapie. Diab Stoffw 1995;4:9-13 (in German).
29. Müller UA, Femerling M, Reinauer KM et al. Intensified treatment and education of type-1 diabetes mellitus as clinical routine: a nation-wide quality-circle experience in Germany. Diab Care 1999;22:B29-34.
30. Schiel R, Müller UA, Kalbas B, Franke I. Diabeteswissen und Lebensqualität zweier Patientengruppen mit intensivierter konventioneller Insulintherapie. Vier Jahre bzw. unmittelbar nach Teilnahme an einem strukturierten 5-Tage-Behandlungsprogramm. Diab Stoffw 1996;5:63-8.
31. Seibold A, Jeckelmann J. GlucOnline - Ein neuer Ansatz zur kontinuierlichen Glukosemessung. Therapieforum Diabetes 2002;1:9-11.
32. Schiel R, Kademann A, Müller UA. Quality of life of patients with continuous subcutaneous insulin infusion. Zprav Klein Farmakol Farmac 1998;12:29-34.
33. Hanaire Broutin H, Broussolie C, Jeandidier N et al. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC study group. Diab Care 1995;18:388-92.
34. Catargi B, Meyer L, Melki V, Renard E, Jeandidier N for the EVADIAC Study Group. Comparison of blood glucose stability and HbA1c between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lisro in type 1 diabetic patients: a pilot study. Diabetes Metab 2002;28:133-7.
35. Steil GM, Loutseiko M, Kurtz N et al. Tuning closed-loop insulin delivery based on known daily insulin requirements. Diabetes 2002;51:510.
36. Renard E, Shah R, Miller M et al. Accuracy of real-time blood glucose measurement by long-term sensor system allows automated insulin delivery in diabetic patients. Diabetes 2002;51:508.
37. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years. Evidence for the expanding use of insulin pump therapy in type 1 diabetes. Diab Care 2002;25:593-8.
38. Bode BW, Sabbah HAT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002;18:S14-20.
39. Leichter SB, Schreiner ME, Reynolds LR, Bolick T. Long-term follow-up of diabetic patients using insulin infusion pumps. Considerations for future clinical application. Arch Int Med 1985;145:1409-12.
40. Mecklenburg RS, Benson EA, Benson JW et al. Long-term metabolic control with insulin pump therapy. Report of experience with 127 patients. N Engl J Med 1985;313:465-8.
41. Wredling R, Lins PE, Adamson U. Factors influencing the clinical outcome of continuous subcutaneous insulin infusion in routine practice. Diab Res Clin Pract 1993;19:59-67.
42. Wredling R, Hannerz L, Johansson UB. Variability of blood glucose levels in patients treated with continuous subcutaneous insulin infusion: a pilot study. Practical Diab Int 1997;14:5-8.
43. Bell DS, Ovalle F. Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy. Endocr Pract 2000;6:357-60.